Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:fungus
|
| gptkbp:associated_with |
gptkb:COVID-19
neutropenia chronic sinusitis |
| gptkbp:caused_by |
gptkb:Mucor_fungi
|
| gptkbp:complications |
gptkb:orbital_cellulitis
cavernous sinus thrombosis disseminated disease pulmonary infection |
| gptkbp:distribution |
worldwide
|
| gptkbp:duration |
weeks to months
|
| gptkbp:end_of_life |
high in untreated cases
|
| gptkbp:first_described_by |
gptkb:19th_century
|
| gptkbp:healthcare |
during COVID-19 pandemic
in immunocompromised populations |
| https://www.w3.org/2000/01/rdf-schema#label |
mucormycosis
|
| gptkbp:is_often_used_in |
diabetic patients
patients with cancer immunocompromised patients patients with HIV/ AIDS patients with organ transplants |
| gptkbp:is_protected_by |
controlling blood sugar
avoiding exposure to mold |
| gptkbp:research_focus |
understanding pathogenesis
improved antifungal therapies risk factor identification |
| gptkbp:risk_factor |
gptkb:Company
immunosuppression corticosteroid use |
| gptkbp:social_responsibility |
gptkb:MRI
CT scan microscopic examination tissue biopsy |
| gptkbp:soil_type |
gptkb:zygomycetes
|
| gptkbp:symptoms |
headache
cough fever nasal congestion chest pain vision changes black lesions on nasal bridge facial swelling |
| gptkbp:transmission |
not contagious
|
| gptkbp:treatment |
gptkb:hospital
gptkb:isavuconazole gptkb:posaconazole gptkb:drug early diagnosis drug resistance liposomal amphotericin B better with combination therapy depends on early treatment poor in advanced cases surgical intervention necessity |
| gptkbp:bfsParent |
gptkb:Zygomycota
|
| gptkbp:bfsLayer |
4
|